Medimmune Limited

Pfizer Corporation

The Brigham and Women's Hospital, Inc.

Millennium Pharmaceuticals Limited

Viela Bio, Inc.

Astrazeneca Ab

The Feinstein Institutes for Medical Research

Flagship Pioneering Innovations Vi, LLC

Anthony Coyle

Herren Wu

Peter Kiener

Ronald Herbst

Changshou Gao

Ling-Ling An

Su-Yau Mao

Juan C Almagro

Christopher C Fraser

Melissa Marie Damschroder

William Dall'Acqua

Lidia Mosyak

Edward Roland Lavallie

Stefano V Gulla

Stacey Drabic

Eric M Bennett

Thomas Thisted

Vaheh Oganesyan

Janet Elizabeth Buhlmann

Sreekumar R Kodangattil

Steven A Greenberg

Christine Huard

David Kenneth Spencer

Stephen Manning

James Perry Hall

Luba Grinberg

Shabazz Novarra

Manuel Baca

Christian B Allan

Jane Tian

Ricardo Cibotti

Theresa O'Keefe

Shixin Qin

Michael A Bowen

Yihong Yao

Gianluca Carlesso

Adam Reid Root

Alexis Hiram Ramos

Kristen Park Hopson

Zachary Kohl Costello

Antonios O Aliprantis

Ryan Terrell Phennicie

Lana Dinic

Karin Alma Frieda Reif

Manual Baca

Bahija Jallal

Michael Bowen

William Dall'acqua

Melissa Damschroder

Jame Perry Hall

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.

Interferon beta antibodies and uses thereof

The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to a thymic stromal lymphopoietin (TSLP) (e.g., a full-length human TSLP). The disclosure also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating a TSLP-associated disease or condition.

Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)

The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.

Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer

Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunit

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN&#x3b2;). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.

The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.

Anti-IFNAR1 antibodies with reduced Fc ligand affinity

CD40L-specific TN3-derived scaffolds and methods of use thereof

The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonization) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.

Humanized anti-CD19 antibodies

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

High affinity antibodies against HMGB1 and methods of use thereof

Growing community of inventors

Boston, MA, United States of America

Anthony Coyle